other material
confidence high
sentiment positive
materiality 0.85
Pliant Therapeutics: Bexotegrast 320 mg shows significant FVC increase in IPF Phase 2a trial
PLIANT THERAPEUTICS, INC.
- 320 mg group met primary/safety endpoints; no drug-related severe/serious adverse events over 12 weeks.
- Mean FVC increase of +29.5 mL from baseline vs placebo decline of 110.7 mL (+140 mL vs placebo, p<0.05 at all timepoints).
- No bexotegrast-treated patients had FVCpp decline ≥10%; QLF progression slowed vs placebo (0.20% vs 1.46%).
- PRO-C3 and integrin beta-6 biomarkers reduced at 4 and 12 weeks (p<0.01 and p<0.0001 vs placebo).
- Phase 2b trial planned for mid-2023; final 24-week data from 320 mg cohort expected Q2 2023.